Local view for "http://purl.org/linkedpolitics/eu/plenary/2012-09-11-Speech-2-371-000"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2012-09-11"^^xsd:date2
dcterms:Is Part Of	lp_eu:Explanations of vote2
dcterms:Language	"fr"^^xsd:language2
lpv:document identification number	"en.20120911.32.2-371-000"2
lpv:hasSubsequent	lp_eu:2012-09-11-Speech-2-371-2502
lpv:speaker	lp:Sylvie Guillaume2
lpv:spokenAs	vice-chair; S&D (2012-06-07--2014-06-30)3,3 substitute; Delegation to the Euro-Latin American Parliamentary Assembly (2009-09-17--2014-06-30)3,3 substitute; FEMM (2012-01-19--2014-06-30)3,3 substitute; AFCO (2012-01-19--2014-06-30)3,3 unknown; Parti socialiste (2009-07-14--2014-06-30)3,3 substitute; Delegation to the EU-Mexico Joint Parliamentary Committee (2009-09-16--2014-06-30)3,3 member; LIBE (2012-01-19--2014-06-30)3,3
lpv:translated text	"Following the scandal surrounding Mediator, which was responsible for 1 000 to 2 000 deaths in France, it has seemed particularly urgent to revise the systems of pharmacovigilance in the European Union, which have a number of profound shortcomings. It is for this reason that I support the work carried out by my colleague, Ms McAvan, to improve detection of dangerous medicines and to speed up their withdrawal from the market. We have a duty to provide measures enabling us to prevent other dangerous medicines from becoming commercially available in the European Union. In addition, we must also consider the question of the influence that the laboratories wield and the pressures that they exert on the administrative authorities."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph